ArticleInternational journal of ophthalmology2017
Vasoactive intestinal peptide, a promising agent for myopia?
Article in International journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Retinal VIP-amacrine cells: their development, structure, and function.Eye (London, England) · 2024Pooled it
- Myopia development: multifactorial interplay, molecular mechanisms and possible strategies.Frontiers in medicine · 2025Review
- Understanding amblyopia from the perspective of neurovascular units: changes in the retina and brain.Frontiers in cell and developmental biology · 2025Review
- Collagen is crucial target protein for scleral remodeling and biomechanical change in myopia progression and control.Heliyon · 2024Review
- Article
- The role of vasoactive intestinal peptide (VIP) in atropine-related inhibition of the progression of myopia.BMC ophthalmology · 2024Article
- The Role of Retinal Dysfunction in Myopia Development.Cellular and molecular neurobiology · 2023Review
- Functions of retinal astrocytes and Müller cells in mammalian myopia.BMC ophthalmology · 2022Article
- Retinal Gene Expression of Selective Genes and Histological Stages of Embryonic and Post-Hatch Chickens (Genes · 2022Article
- Therapeutic effect of vasoactive intestinal peptide on form-deprived amblyopic kittens.BMC ophthalmology · 2019Article
- Retinoprotective Effects of TAT-Bound Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase Activating Polypeptide.Journal of molecular neuroscience : MN · 2019Article
- IMI - Report on Experimental Models of Emmetropization and Myopia.Investigative ophthalmology & visual science · 2019Review
- Vagal Nerve Stimulation Attenuates Ischemia-Reperfusion Induced Retina Dysfunction in Acute Ocular Hypertension.Frontiers in neuroscience · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the role of vasoactive intestinal peptide (VIP) in form-deprivation myopia (FDM).
methodsFDM was created in three groups of eight chicks by placing a translucent diffuser on their right eyes. Intravitreal injections of saline and VIP were applied once a day into the occluded eyes of groups 2 and 3, respectively. Retinoscopy and axial length (AL) measurements were performed on the first and 8
resultsThe median final refraction (D) in right eyes were -13.75 (-16.00, -12.00), -11.50 (-12.50, -7.50), and -1.50 (-4.75, -0.75) in groups 1, 2, and 3, respectively (
conclusionVIP has potential inhibitory effects in the development of FDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.